December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Barinthus Biotherapeutics plc - American Depositary Shares (NQ:BRNS)

0.7476 -0.0103 (-1.36%)
Streaming Delayed Price Updated: 3:04 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Barinthus Biotherapeutics plc - American Depositary Shares

< Previous 1 2 3 Next >
News headline image
Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Biotherapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate Cancer
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
BRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024 ↗
BRNS stock results show that Barinthus Biotherapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Barinthus Bio Reports Second Quarter 2024 Update on Corporate Developments and Financial Results
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q1 2024 ↗
BRNS stock results show that Barinthus Biotherapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
Dr. Hooftman brings more than 25 years’ experience in international drug development including immunology, autoimmunity, hematology, oncology, and infectious diseases 
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives ↗
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were noted,... 
Via Benzinga
News headline image
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
BRNS Stock Earnings: Barinthus Biotherapeutics Beats EPS for Q4 2023 ↗
BRNS stock results show that Barinthus Biotherapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
From Barinthus Biotherapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.